David Teachey Laboratory

Ongoing Research

Clinical trials are underway at the Center for Childhood Cancer Research to evaluate the use of sirolimus as a treatment for refractory pediatric autoimmune diseases.

Clinical studies conducted by physician scientists at the CCCR have demonstrated that administration of tocilizumab — a recombinant humanized anti-IL6 receptor monoclonal antibody that interferes with secretion of the cytokine IL6 — can be an effective treatment for pediatric patients who develop cytokine release syndrome (CRS) after CART or BiTE therapy.